miR-200c controlled cell cycle progression and cell growth by down-regulating the G1-S regulator CDK2, and had anti-cancer impacts in ccRCC (Wang et al., 2015). This evidence concerns the gene CDK2 and nonpapillary renal cell carcinoma.